Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P571

Beliefs about Medicines Questionnaire assessing medication adherence in patients with inflammatory bowel disease

Authors:

M. L. De Castro*1, A. Martín2, L. Sanromán1, N. Martínez2, M. Figueira1, V. Hernández1, J. R. Pineda1, S. Pereira1, J. Martínez-Cadilla1, V. Del Campo3, J.-I. Rodríguez-Prada1

1Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Gastroenterology, Vigo, Spain, 2Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Hospital Pharmacy, Vigo, Spain, 3Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Epidemiology, Vigo, Spain

P572

Dysplasia in inflammatory bowel disease: Is endoscopic mucosal resection ready for prime-time?

Authors:

D. Branquinho*, F. Portela, P. Freire, M. Ferreira, S. Mendes, M. Ferreira, C. Sofia

Coimbra University Hospital Centre, Gastroenterology, Coimbra, Portugal

P573

Assessment of serum C-reactive protein, faecal lactoferrin, and faecal calprotectin in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 Ustekinumab induction studies

Authors:

C. Gasink*1, Y. Lang1, D. Jacobstein1, J. Johanns1, P. Rutgeerts2, W. de Villiers3, J.-F. Colombel4

1Janssen R & D, LLC, Spring House, Pennsylvania, United States, 2University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, 3Universiteit Stellenbosch University, Stellenbosch, South Africa, 4Mount Sinai, Icahn School of Medicine, New York, New York, United States

P574

Effect of adalimumab on clinical outcomes and health-related quality of life amongst patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Authors:

S. Travis*1, B. Feagan2, L. Peyrin-Biroulet3, R. Panaccione4, S. Danese5, A. Lazar6, A. Robinson7, J. Petersson7, M. Bereswill6, M. Skup7, N. Chen7, S. Wang7, R. Thakkar7, J. Chao7

1Oxford University Hospitals, Oxford, United Kingdom, 2Robarts Research Institute, Ontario, Canada, 3University Hospital of Nancy, Les Nancy, France, 4University of Calgary, Medicine, Calgary, Canada, 5Istituto Clinico Humanitas, Milan, Italy, 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 7AbbVie Inc., North Chicago, Illinois, United States

P575

Efficacy of faecal diversion in managing refractory perianal or colonic Crohn’s disease

Authors:

I. Parisi*1, R. Vega1, S. McCartney1, C. Hart2, S. Bloom1

1University College London Hospital, Department of Gastroenterology, London, United Kingdom, 2University College London Hospital, GI Surgery Department, London, United Kingdom

P576

Long-term efficacy and safety of adalimumab in paediatric patients with Crohn’s disease

Authors:

W. A. Faubion*1, M. Dubinsky2, F. M. Ruemmele3, J. Escher4, J. Rosh5, J. S. Hyams6, S. Eichner7, Y. Li7, N. Reilly7, A. M. Robinson7, A. Lazar8

1Mayo Clinic, Rochester, Minnesota, United States, 2Icahn School of Medicine at Mount Sinai, New York, New York, United States, 3Universite Sorbonne Paris-Cite, Hospital Necker-Enfants Malades, Paris, France, 4Erasmus MC-Sophia Children’s Hospital, Rotterdam, Netherlands, 5Goryeb Children’s Hospital/Atlantic Health, Morristown, New Jersey, United States, 6Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 7AbbVie Inc., North Chicago, Illinois, United States, 8AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

P577

Croatian database from 5 centres: efficacy and safety of infliximab biosimilar in treatment of inflammatory bowel disease score patients

Authors:

N. Turk*1, M. Brinar1, 2, D. Grgic1, A. Kunovic1, R. Prijic1, V. Borzan3, B. Sincic Mijandrusic4, M. Crncevic Urek5, M. Banic5, I. Tadin Hadina6, Z. Puljiz6, M. Simunic6, N. Rustemovic1, 2, S. Cukovic Cavka1, 2, Z. Krznaric1, 2

1University Hospital Centre ‘Zagreb’, Gastroenterology and hepatology, Zagreb, Croatia, 2University of Zagreb, School of medicine, Zagreb, Croatia, 3University Hospital Centre ‘Osijek’, Gastroenterology and hepatology, Osijek, Croatia, 4University Hospital Centre ‘Rijeka’, Gastroenterology and hepatology, Rijeka, Croatia, 5Clinical Hospital ‘Dubrava’, Gastroenterology and hepatology, Zagreb, Croatia, 6University Hospital Centre ‘Split’, Gastroenterology and hepatology, Split, Croatia

P578

Changes of practice in ileoanal pouch surgery in a single referral centre

Authors:

A. Germain*1, A. de Buck van Overstraeten2, A. Wolthuis2, A. D’Hoore2

1University Hospital of Nancy, Department of Digestive Surgery, Nancy, France, 2University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium

P578

Inflammatory bowel disease patients’ preference for disease treatment factors

Authors:

J. Gregor1, M. Williamson*2, D. Dajnowiec2, B. Sattin2, E. Sabot3, B. Salh4

1Western University and London Health Sciences Centre, London, Ontario, Canada, 2Janssen Inc., Toronto, Canada, 3Optum Inc., Cambridge, Massachusetts, United States, 4University of British Columbia, Gastroenterology, Vancouver, Canada

P579

Combined therapy of tacrolimus and vedolizumab in severe refractory ulcerative colitis

Authors:

N.-A. Dietrich*1, F. Baer1, A. Dignass2, B. Bokemeyer3, K. Fellermann1, J. Buening1

1University Hospital of Schleswig-Holstein, Luebeck, Internal Medicine, Luebeck, Germany, 2Hospital Agaplesion Markus, Frankfurt am Main, Department of Medicine I, Frankfurt am Main, Germany, 3Gastroenterology Practice Minden, Gastroenterology, Minden, Germany

P581

Bleeding after side-to-side isoperistaltic strictureplasty for Crohn’s disease: Is it still a major surgical complication?

Authors:

F. Giudici*1, S. Scaringi1, F. Ficari1, D. Zambonin1, C. Di Martino1, M. Fazi1, F. Tonelli2, P. Bechi1

1Careggi University Hospital, Surgery and Translational Medicine, Florence, Italy, 2University of Florence, Florence, Italy

P582

Predictive value of infliximab trough levels in quiescent inflammatory bowel disease under maintenance infliximab therapy

Authors:

M. Bejaoui*, F. Charbit-Henrion, C. Landman, H. Sokol, A. Bourrier, I. Nion-Larmurier, J. Cosnes, L. Beaugerie, P. Seksik

Saint Antoine Hospital, Gastroenterology & Nutrition, Paris, France

P583

Real-world use and effectiveness of golimumab for ulcerative colitis in Canada

Authors:

B. Bressler1, M. Williamson*2, F. Camacho3, B. Sattin2, A. H. Steinhart4

1University of British Columbia, Vancouver, Canada, 2Janssen Inc, Toronto, Canada, 3Damos Inc, Toronto, Canada, 4University of Toronto, Toronto, Canada

P584

Relapse risk and predictors for relapse in a real-life cohort of inflammatory bowel disease patients after discontinuation of anti-tumour necrosis factor therapy

Authors:

S. Bots*, S. Kuin, M. Löwenberg, C. Ponsioen, G. van den Brink, G. D’Haens

Academic Medical Centre (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands

P585

Systematic literature review of clinical trials that assess the efficacy of biologic drugs in the treatment of extraintestinal manifestations in inflammatory bowel disease

Authors:

G. Van Assche1, L. Peyrin-Biroulet2, D. Gomez-Ulloa3, L. Garcia-Alvarez3, N. Lara3, C. Black4, S. Kachroo*4

1University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 2Lorraine University, Gastroenterology Department, Vandoeuvre, France, 3IMS Health, Real-World Evidence Solutions, Barcelona, Spain, 4Merck & Co, Inc, Centre for Observational and Real-World Evidence (CORE), Rahway, New Jersey, United States

P586

Cyclophosphamide pulse therapy in severe refractory Crohn’s disease

Authors:

F. Baer*1, T. Krause2, A. Stallmach3, N. Teich4, C. Maaser5, J. Maul6, U. Helwig7, K. Fellermann1, J. Buening1

1University hospital of Luebeck, Department of Internal Medicine I, Luebeck, Germany, 2Gastroenterologie Opernstraße, Kassel, Germany, 3University Hospital of Jena, Department of Gastroenterology, Jena, Germany, 4Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten, Leipzig, Germany, 5Hospital Lüneburg, Department of Internal Medicine, Lüneburg, Germany, 6Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Department of Medicine I, Berlin, Germany, 7Internistische Praxengemeinschaft Oldenburg, Oldenburg, Germany

P587

SuPREMe-CD Study: surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease—preliminary results and trial protocol

Authors:

G. Luglio*, M. C. Giglio, A. Rispo, R. Peltrini, M. Sacco, V. Sollazzo, C. Bucci, E. Spadarella, F. Terracciano, G. D. De Palma, L. Bucci

Federico II University of Naples, Department of Clinical Medicine and Surgery, Naples, Italy

P588

Test characteristics of commonly used clinical and biochemical markers predicting mucosal healing and active inflammation in ulcerative colitis: faecal calprotectin is clearly superior

Authors:

K. Carlsen*1, 2, R. Goll3, 4, H. Elsberg5, T. Thorkilgaard5, L. Maagaard5, S. S. Wergeland6, J. Florholmen4, C. Jakobsen2, V. Wewer2, L. B. Riis1, P. S. Munkholm3

1Herlev Hospital, Department of Pathology, Herlev, Denmark, 2Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, 3North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark, 4University Hospital of North Norway, Department of Gastroenterology, Tromsoe, Norway, 5Herlev Hospital, Department of Gastroenterology, Herlev, Denmark, 6University Hospital of North Norway, Department of Clinical Pathology, Tromsoe, Norway

P589

Clinical analysis of the postoperative bowel function in elderly patients with ulcerative colitis

Authors:

R. Futatsuki*1, A. Sugita1, K. Koganei1, K. Tatsumi1, H. Kuroki1, K. Yamada1, K. Arai1, H. Kimura2, T. Fukushima3

1Yokohama Municipal Citizens Hospital, Inflammatory Bowel Disease Centre, Department of Surgery, Yokohama, Japan, 2Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Department of Surgery, Yokohama, Japan, 3Matsushima Clinic, Yokohama, Japan

P590

Therapeutic drug monitoring is a new tool for improving the care of patients treated by anti-tumour necrosis factor-alpha: Does this apply to children with inflammatory bowel diseases?

Authors:

M. Chavannes*1, P. Jantchou1, F. Gervais1, R. Robitaille2, V. Marchand1, C. Deslandres3

1Sainte Justine University Hospital, Paediatric Gastroenterology, Montreal, Canada, 2Hôpital Maisonneuve Rosemont, Biochemistry, Montreal, Canada, 3Sainte Justine University Hospital, Montreal, Canada